Year: 2025

Volta Finance Limited (VTA / VTAS)September 2025 monthly report NOT FOR RELEASE, DISTRIBUTION, OR PUBLICATION, IN WHOLE OR PART, IN OR INTO THE UNITED STATES Guernsey, September 24th 2025 AXA IM has published the Volta Finance Limited (the “Company” or “Volta Finance” or “Volta”) monthly report for September 2025. The full report is attached to this release and will be available on Volta’s website shortly (www.voltafinance.com). Performance and Portfolio Activity Dear Investors, In September, Volta Finance achieved a net performance of +0.3% bringing year-to-date performance to +3.5%. This performance can be compared with US High Yield and Euro High Yield which respectively returned +7.1%*** and +4.6% over the same period and Morningstar Leveraged Loan indices which returned +4.6%*** in the US and +3.6% in Europe. Global markets showed...

NEW YORK, Oct. 24, 2025 (GLOBE NEWSWIRE) — via InvestorWire — Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) today announces its placement in an editorial published by NetworkNewsWire (“NNW”), one of 70+ brands within the Dynamic Brand Portfolio@IBN (InvestorBrandNetwork), a specialized communications platform with a focus on financial news and content distribution for private and public companies and the investment community. To view the full publication, “Investors Turn to AI-Driven Imaging Firms Targeting High-Growth Breast Cancer Market,” please visit: https://nnw.fm/qBAbh Artificial intelligence (AI) continues to transform healthcare innovation, with medical imaging emerging as one of its most promising frontiers. In breast cancer detection, where early identification often determines patient outcomes, AI-powered...

– 100% response rate in 1L left-sided mCRC (n=8, confirmed and unconfirmed) – 62% response rate in 2L left- and right-sided mCRC (n=13, confirmed and unconfirmed)  UTRECHT, The Netherlands and CAMBRIDGE, Mass., Oct. 24, 2025 (GLOBE NEWSWIRE) — Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), an oncology company developing innovative, full-length multispecific antibodies and antibody drug conjugates (Biclonics®, Triclonics® and ADClonics®), today announced interim clinical data as of a July 29, 2025 data cutoff from the ongoing phase 2 trial of the bispecific antibody petosemtamab in combination with standard of care FOLFOX/FOLFIRI in 1L and 2L metastatic colorectal cancer (mCRC), and petosemtamab monotherapy in 3L+ mCRC. These data will be presented in a plenary session oral presentation by Dr. Moh’d Khushman M.D., Washington...

SHENZHEN, China, Oct. 24, 2025 (GLOBE NEWSWIRE) — MicroCloud Hologram Inc. (NASDAQ: HOLO), (“HOLO” or the “Company”), a technology service provider, proposed a Quantum Convolutional Neural Network (QCNN) based on hybrid quantum-classical learning and successfully applied it to the multi-class classification problem on the MNIST dataset, achieving accuracy comparable to classical Convolutional Neural Networks (CNNs). This achievement not only demonstrates the practical feasibility of quantum computing in machine learning tasks but also provides a new pathway for application exploration in the subsequent NISQ (Noisy Intermediate-Scale Quantum) era. The multi-class classification problem is one of the most common tasks in computer vision and artificial intelligence applications. Whether in image recognition, handwritten...

Worcester, MA, Oct. 24, 2025 (GLOBE NEWSWIRE) — Vystar® Corporation (OTCQB: VYST) Vystar announced today the Internet and Incubator Stock Review has initiated coverage. “We followed the team at Vystar over the past decade, as they assembled a portfolio of best-of-breed start-ups and companies. Vystar’s goal has been to provide each of the companies with development assistance (management, corporate structuring and marketing) to the extent they could generate revenues and achieve profitability on a standalone basis.” Vystar has four start-ups under its umbrella, with the most recent addition GoPaid.com exhibiting breakthrough potential.Vystar’s Vytex™ is a rubber hydrocarbon material with the proteins and non-rubber components that cause allergies removed to create an ultra-pure latex and dry rubber with...

TORONTO, Oct. 24, 2025 (GLOBE NEWSWIRE) — Middlefield Global Dividend Growers ETF (TSX: MDIV) (the “Fund”) is pleased to announce that distributions for the fourth quarter of 2025 will be payable to unitholders of Middlefield Global Dividend Growers ETF as follows:Record Date Payable Date Distribution Per Trust UnitOctober 31, 2025 November 14, 2025 $0.06November 30, 2025 December 15, 2025 $0.06December 31, 2025 January 15, 2026 $0.06The trust units trade on the Toronto Stock Exchange under the symbol MDIV. The Fund offers a distribution reinvestment plan (“DRIP”) for unitholders which provides unitholders with the ability to automatically reinvest distributions, commission free, and realize the benefits of compound growth. Unitholders can enroll in the DRIP program by contacting their investment advisor. Middlefield...

Institutional Interest Surging DENVER, Oct. 24, 2025 (GLOBE NEWSWIRE) — 247marketnews.com, a pioneer in digital media dedicated to the swift distribution of financial market news and corporate information, reports that Wall Street and Madison Avenue are finally catching up to what early investors already knew: VENU (NYSE American: VENU) isn’t just another real estate play it’s building the infrastructure for America’s next entertainment revolution. VENU will offer fractional ownership opportunities to some of the most modern, sophisticated amphitheaters in the country! VENU has launched a nationwide advertising campaign airing across five major U.S. media networks; FOX News, FOX Business, CNBC, Peacock, and Newsmax, reaching millions of viewers through both broadcast and streaming platforms. The campaign started October 15th and...

FDA-approved Emrosi (40 mg Minocycline Hydrochloride Modified-Release Capsules, 10 mg immediate release and 30 mg extended release) is available in the United States for the treatment of inflammatory lesions of rosacea in adults DFD-29 demonstrated superior efficacy in IGA success rates and inflammatory lesion counts versus both placebo and doxycycline (P